The studies exist. That already puts this product ahead of most of the shelf. The question is what they can carry — and there is a specific pharmacological objection worth understanding before you decide.
The research is real but thin, old and unreplicated. The active ingredient is silk protein hydrolysate — sold as Cera-Q, studied as BF-7 — at 100 mg twice daily, so 200 mg a day. Randomised, double-blind, placebo-controlled studies exist, reporting memory improvements over three to four weeks at doses of 200, 280 and 400 mg. But the trials are small and short, and no substantial new independent research has replicated them in recent years.
And there’s a specific objection. A proposed class action filed 22 November 2021 — Scarpo v. Natrol, LLC — alleges the ingredient is “no more effective than a placebo” and, via the plaintiff’s expert, that it “cannot impact the brain because it does not absorb into the blood stream or cross the blood-brain barrier.” Those are allegations; no finding of wrongdoing has been established. 🧠
- First, the credit it deserves
- What the studies actually are
- The dose criticism doesn’t hold
- The problem that does hold
- The blood-brain barrier question
- The 2021 complaint, precisely
- What “improved memory scores” means
- Four weeks is a very short trial
- Our verdict
- What has better evidence
- The appointment worth making
- Frequently asked questions
- Your checklist
First, the credit it deserves
It’s worth starting fairly, because this product is not typical of its category.
- It has one named active ingredient, not a fifteen-item proprietary blend. You can see exactly what you’re getting.
- The amount is disclosed — 100 mg per tablet, twice daily.
- There is no stimulant. No caffeine masquerading as cognitive enhancement.
- Actual randomised, double-blind, placebo-controlled studies exist for the ingredient. Most brain supplements have nothing of the kind.
That’s a meaningfully better starting position than most of the aisle. The criticisms that follow are about what the evidence can support — not about the product being dishonestly assembled.
What the studies actually are
| Element | Detail |
|---|---|
| Ingredient | Silk protein hydrolysate (Cera-Q; BF-7 in the literature) |
| Product dose | 100 mg × 2 daily = 200 mg/day |
| Study doses | 200 mg, 280 mg and 400 mg daily |
| Duration | Around three to four weeks |
| Design | Randomised, double-blind, placebo-controlled |
| Outcome measured | Memory scores, including Rey-Kim memory scores |
| Independent replication | Not found in recent years |
The manufacturer describes a set of clinical studies across adults, seniors and children reporting statistically significant improvements in memory and cognition in four weeks or less. In one, participants took 200 mg or 400 mg of BF-7 or placebo for three weeks, with both active groups showing increases in Rey-Kim memory scores.
The dose criticism doesn’t hold
You’ll see it repeated online that Cognium contains far less than the studies used. We checked, and for the standard product that’s wrong.
The tablet is 100 mg, taken twice daily, giving 200 mg per day — which matches the lower dose arm used in the research. Other cited studies used 280 mg and 400 mg, and the Extra Strength version moves the dose upward.
We’re correcting this because it matters for how you weigh the product: if the dose were the problem, you could fix it by taking more tablets. The actual limitation is different, and it isn’t fixable by any consumer action.
The problem that does hold
Here is the real weakness, and it’s structural.
The evidence base is small, short and static. The trials involve modest numbers of participants over three to four weeks, and there has been no substantial new independent research — no new randomised trials, meta-analyses or systematic reviews from unconnected researchers establishing the effect.
Research follows results. An ingredient that reliably improved memory in randomised trials would be one of the most commercially and scientifically interesting compounds in nutrition — it would attract independent groups wanting to confirm, extend and explain it. Instead the evidence base sits where it was, cited by the people selling it.
That’s not proof the ingredient doesn’t work. Funding is unevenly distributed and some genuine findings languish. But when a promising result stands alone for years, the most common explanation is that it didn’t hold up when others looked — and studies that fail to replicate are far less likely to be published than ones that succeed.
The blood-brain barrier question
This is the most interesting scientific objection, and it’s worth understanding independently of who is making it.
The ingredient is a protein hydrolysate — protein broken into peptide fragments. For it to affect memory directly, a meaningful quantity would need to survive digestion, be absorbed intact, and then cross the blood-brain barrier, a highly selective interface that exists specifically to keep most circulating molecules out of the brain.
Each of those is a genuine hurdle. Peptides are broken down by digestive enzymes; absorption of intact peptides is limited; and the blood-brain barrier excludes most peptides and proteins by design. Getting a specific peptide into the brain is one of the hardest problems in pharmacology — an entire field exists around solving it.
None of this proves the ingredient does nothing. Compounds can act peripherally and produce central effects indirectly. But it means the mechanism needs explaining rather than assuming, and “how does it reach the brain?” is a fair question to put to any protein-based nootropic.
The 2021 complaint, precisely
There is litigation on the public record, and how much weight it carries depends entirely on what it is.
On 22 November 2021, a proposed class action — Scarpo v. Natrol, LLC — was filed in federal court in California under California’s Unfair Competition Law and Consumers Legal Remedies Act, on behalf of a proposed class of California purchasers. It alleges that Natrol falsely advertises that Cognium Memory and Cognium Memory Extra Strength improve memory and recall, that the active ingredient “is no more effective than a placebo,” and — citing the plaintiff’s expert — that Cognium “cannot impact the brain because it does not absorb into the blood stream or cross the blood-brain barrier.”
Everything above is an allegation. A complaint is one side’s account, drafted by the plaintiff’s lawyers to persuade. No finding of wrongdoing has been established by it, and we found no reported settlement or judgment.
Do not read this as a court concluding the product doesn’t work. Read it as: a formal legal challenge exists, and it advances a specific, testable pharmacological argument about absorption and the blood-brain barrier that you can weigh on its own merits — and put to the manufacturer.
What “improved memory scores” means
A statistically significant improvement on a memory test is not the same as a difference you would notice, and the gap between them is where most supplement marketing lives.
Three questions separate a meaningful result from a technically-true one:
- How large was the change? Statistical significance says an effect probably isn’t chance. It says nothing about size. A small, real improvement on a test score may be undetectable in daily life.
- Does the test predict real-world function? Formal memory tests are useful research tools; they are not the same as remembering where you left your keys or a colleague’s name.
- Who was tested? An effect in one group — young, old, cognitively impaired, healthy — doesn’t automatically transfer to another.
None of that is unique to this product. It applies to every cognitive supplement claim you’ll ever read.
Four weeks is a very short trial
The studies ran roughly three to four weeks. For a product people take for months or years, that’s a significant limitation and it cuts in both directions.
- Durability is unknown. An effect at four weeks may grow, plateau or fade. Nobody has published the answer.
- Long-term safety is uncharacterised. Short trials cannot detect uncommon or slow-developing effects.
- It doesn’t match how people use it. Anyone worried about memory is thinking in years, not weeks.
- Short trials favour transient effects — including novelty, attention and expectation.
Our verdict
| Question | Answer |
|---|---|
| Does randomised evidence exist? | Yes — better than most of the category |
| Is the dose adequate? | Yes — 200 mg/day matches the lower study arm |
| Is the evidence base large? | No — small and short |
| Has it been independently replicated? | Not that we could find |
| Is the mechanism established? | Absorption and brain delivery are open questions |
| Has a court found it ineffective? | No — allegations only |
| Would we recommend it? | No — but it’s a defensible personal choice |
The honest summary: this is a thin, ageing, unreplicated evidence base rather than a fabricated one. That’s a real distinction. It also falls well short of what would justify relying on it — particularly if memory is genuinely worrying you.
What has better evidence
The 2024 Lancet Commission on dementia prevention identified fourteen modifiable risk factors and estimated that eliminating all of them could potentially prevent 45% of future dementia: hearing loss, hypertension, high LDL cholesterol, obesity, excessive alcohol, traumatic brain injury, smoking, depression, physical inactivity, diabetes, social isolation, air pollution, untreated vision loss and low education.
Nothing on that list is sold in a bottle. Two are routinely ignored: hearing loss is a leading modifiable factor and hearing aids are badly under-used, and untreated vision loss joined the list in 2024 — meaning an overdue eye test is better supported than any nootropic on the shelf.
Our companion piece on this product’s safety profile covers the reversible causes of memory problems in more detail.
Simple Step Counter
Physical inactivity is one of the fourteen modifiable dementia risk factors — and walking is the version of that most people will actually do
If the goal is protecting cognition, the strongest evidence points at things you do rather than things you swallow. Physical inactivity appears on the 2024 Lancet Commission’s list of fourteen modifiable risk factors, alongside hearing loss, hypertension and the rest — factors the Commission estimated could account for up to 45% of future dementia if all were eliminated. A basic step counter works because it makes an invisible behaviour visible: most people substantially overestimate how much they move. Establish your actual baseline for a week before setting any target, then increase gradually rather than jumping to an arbitrary round number. A simple dedicated counter is often better than a phone for this, because it’s always on you and doesn’t depend on remembering to carry anything. This supports a broader plan — it isn’t a treatment, and it doesn’t replace seeing a doctor about memory concerns.
- Measure a week’s baseline before setting any target
- Increase gradually — arbitrary round numbers cause people to quit
- Also act on hearing and vision — both are on the same list
- Ask your doctor about blood pressure and cholesterol
- See a doctor about memory concerns — this is not a substitute
The appointment worth making
Memory problems can be caused by vitamin B12 deficiency, thyroid disease, depression, sleep apnoea, alcohol, hearing loss, or a medication you’re already taking — all treatable, several fully reversible, and several identifiable from a single blood test.
A supplement with a benign safety profile provides no protection against any of that, and its very harmlessness makes it easier to keep taking while the real cause continues. Ask specifically for a memory assessment, bring a list of everything you take, and ask about B12, thyroid function and your current medications. Seek assessment promptly for rapid decline over weeks, getting lost in familiar places, difficulty with long-familiar tasks, or if people around you are concerned even when you aren’t.
Frequently asked questions
Does Natrol Cognium actually work?
The honest answer is that the evidence is real but too thin to rely on. Randomised, double-blind, placebo-controlled studies of silk protein hydrolysate exist and reported memory improvements over three to four weeks at 200, 280 and 400 mg daily. But they’re small, short, and — critically — no substantial independent research has replicated them in recent years. An ingredient with a reliable memory effect would normally attract far more attention than this one has.
Is the dose too low?
No — this common criticism doesn’t survive checking. The standard product is 100 mg per tablet taken twice daily, so 200 mg a day, which matches the lower dose arm used in the research; other studies used 280 mg and 400 mg. We’re correcting it because the distinction matters: if dose were the problem you could fix it by taking more tablets. The actual limitation — a small, short, unreplicated evidence base — can’t be fixed by anything you do.
What’s the blood-brain barrier argument?
The ingredient is a protein hydrolysate — protein broken into peptide fragments. To act directly on memory, a meaningful amount would need to survive digestion, be absorbed intact, and cross the blood-brain barrier, a highly selective interface that exists precisely to keep most circulating molecules out of the brain. Each step is a genuine hurdle, and delivering specific peptides into the brain is one of pharmacology’s hardest problems. It doesn’t prove the ingredient does nothing, but it means the mechanism needs explaining rather than assuming.
Did a court rule that it doesn’t work?
No. A proposed class action, Scarpo v. Natrol, LLC, was filed on 22 November 2021 in federal court in California, alleging that the active ingredient is “no more effective than a placebo” and — via the plaintiff’s expert — that Cognium “cannot impact the brain because it does not absorb into the blood stream or cross the blood-brain barrier.” Those are allegations in a complaint, written by the plaintiff’s lawyers. No finding of wrongdoing has been established, and we found no reported settlement or judgment.
Why does independent replication matter so much?
Because research follows results. An ingredient that reliably improved memory in randomised trials would be enormously interesting both scientifically and commercially, and independent groups would want to confirm and explain it. When a promising finding instead sits unchanged for years, cited mainly by the people selling it, the most common explanation is that it didn’t hold up when others looked — and negative replications are much less likely to be published than positive results.
What should I do instead?
See a doctor first — memory problems can be caused by B12 deficiency, thyroid disease, depression, sleep apnoea, alcohol, hearing loss or your current medications, all treatable and several reversible. Then act on the 2024 Lancet Commission’s fourteen modifiable risk factors, which it estimated could account for up to 45% of future dementia: hearing loss, hypertension, high LDL, obesity, alcohol, head injury, smoking, depression, physical inactivity, diabetes, social isolation, air pollution, untreated vision loss and low education. Getting your hearing and vision tested is better supported than any supplement on the shelf.
Your checklist
- Credit that real randomised evidence exists — unusual for this category
- Know the ingredient: silk protein hydrolysate, 200 mg/day
- The dose criticism is wrong — it matches the lower study arm
- The real weakness is small, short and unreplicated studies
- Ask how it reaches the brain — absorption and BBB are open questions
- Treat the 2021 complaint as allegations, not a verdict
- Distinguish statistical significance from a noticeable difference
- Note the trials ran three to four weeks, not years
- Apply the replication test to any supplement’s research
- See a doctor before trying any memory supplement
- Ask about B12, thyroid, depression, sleep apnoea and medications
- Get your hearing and vision tested
- Act on the fourteen modifiable risk factors
Medical disclaimer. This article is general information and not medical advice. Memory problems require medical assessment, not self-treatment. Do not use a supplement in place of seeing a doctor, and do not start, stop or change any prescribed medication — including dementia medication — without speaking to your prescriber. Do not take this product if you have a silk allergy. Not studied in pregnancy or breastfeeding. Seek assessment promptly for rapid cognitive decline over weeks, getting lost in familiar places, difficulty with long-familiar tasks, or if people around you are concerned.
Affiliate disclosure. Some links on this page are affiliate links. As an Amazon Associate we earn from qualifying purchases. We have not recommended the product this article assesses.
